Research progress on the application of botulinum toxin type A in the treatment of myogenous temporoman-dibular disorders
10.12016/j.issn.2096-1456.2024.06.010
- VernacularTitle:A型肉毒素治疗肌源性颞下颌关节紊乱病的研究进展
- Author:
Yifan CHEN
1
;
Liangchen TANG
;
Min'er CHEN
;
Xiao ZHANG
;
Kuangyun TANG
;
Zhiyong LI
Author Information
1. 浙江大学医学院附属口腔医院口腔颌面外科 浙江大学口腔医学院 浙江省口腔疾病临床医学研究中心 浙江省口腔生物医学研究重点实验室 浙江大学癌症研究院 口腔生物材料与器械浙江省工程研究中心,浙江 杭州(310006)
- Keywords:
botulinum toxin type A;
myogenous temporomandibular disorders;
temporomandibular disorders;
masticatory muscles;
myalgia;
acetylcholine;
adverse effects;
clinical application
- From:
Journal of Prevention and Treatment for Stomatological Diseases
2024;32(6):470-477
- CountryChina
- Language:Chinese
-
Abstract:
Myogenous temporomandibular disorder(M-TMD)is one of the main subtypes of temporomandibular dis-order(TMD)and typically manifests as masticatory myofascial pain;the incidence of TMD has been increasing annually in recent years.Botulinum toxin type A(BTX-A)is a potent neurotoxin produced by Clostridium botulinum.BTX-A in-hibits the release of acetylcholine from the presynaptic membrane,thereby blocking neuromuscular junction signaling.The noncosmetic application of BTX-A in the oral and maxillofacial regions is a prominent research topic.In recent years,an increasing number of studies have focused on the application of BTX-A in the treatment of M-TMD.The re-sults of a literature review revealed that an appropriate dose(10-50 U unilaterally)of BTX-A administered in a single in-jection into the masticatory muscles can effectively treat myalgia over a period of 3-6 months.Common adverse effects,such as masticatory weakness and facial paralysis,are transient and can be avoided by standardized injection tech-niques.However,there is a lack of standardized guidelines for injection techniques in clinical practice.
